JAZZ — Jazz Pharmaceuticals plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1232524 · Ireland
Last close
$237.95
Market Cap
$15.45B
52W High
$266.38
52W Low
$125.79
ADV30
931,037
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,208,300,000 1,091,900,000 325,200,000 192,800,000 11,080,900,000 1,619,800,000 6,279,200,000
Mar 2026 1,068,900,000 934,800,000 336,600,000 293,100,000 11,859,600,000 1,844,300,000 7,327,300,000
Dec 2025 1,197,926,000 1,044,398,000 254,535,000 203,451,000 11,659,340,000 1,391,899,000 7,340,756,000
Sep 2025 1,126,107,000 997,227,000 100,009,000 251,412,000 11,356,485,000 1,326,070,000 7,397,455,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,661,073,000
Investing CF
$-221,913,000
Financing CF
$-1,008,480,000
CapEx
$-349,952,000
Dividends Paid
—
Buybacks
$-23,000
EPS Diluted TTM
$14.50
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$1,132,000,000
Inventory
$443,000,000
Receivables
$880,900,000
ST Investments
$580,000,000
EBIT TTM
$898,688,000
Pretax Income TTM
$727,706,000
Interest Exp TTM
$170,982,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,601,286,144
EBITDA
$1,927,067,008
Free Cash Flow
$1,429,392,896
Enterprise Value
$18,165,504,000
Total Cash
$2,199,800,064
Total Debt
$4,409,299,968
Shares Out
64,914,577
Trailing EPS
$14.60
Book Value
$74.10
ROE
22.1%
ROA
6.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,267,586,000 517,622,000 -356,148,000 11,659,340,000 7,340,756,000 4,318,584,000 1,355,773,000
Dec 2024 4,068,950,000 726,630,000 560,120,000 12,012,257,000 7,918,501,000 4,093,756,000 1,395,908,000
Dec 2023 3,834,204,000 597,580,000 414,832,000 11,393,359,000 7,656,362,000 3,736,997,000 1,092,007,000
Dec 2022 3,659,374,000 512,268,000 -224,060,000 10,835,255,000 7,749,521,000 3,085,734,000 1,271,977,000

TTM Snapshot

Revenues TTM
$3,865,561,000
NetIncome TTM
$249,727,000
OpCashFlow TTM
$0
Assets (Latest)
$11,659,300,000
Forward EPS
$25.77

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $190.00 · spot: $237.95 · call volume: 65 · put volume: 34
Expected Move to 2027-01-15: ±$43.90 (18.45%) — implied range $194.05 – $281.85 · ATM straddle on $240.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ASND Ascendis Pharma A/S $14.84B $225.60 —
BBIO BridgeBio Pharma, Inc. $12.82B $65.57 —
CORT CORCEPT THERAPEUTICS INC $12.55B $116.10 —
SMMT Summit Therapeutics Inc. $12.45B $15.61 —
MDGL MADRIGAL PHARMACEUTICALS, INC. $11.93B $516.56 —

News headlines (Yahoo Finance, 1h cache)

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
2026-09-20 20:02 · Yahoo
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
2026-09-18 10:42 · Yahoo
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
2026-09-18 02:56 · Yahoo
Jazz Pharmaceuticals (JAZZ) Eyes Ziihera Trials In Breast Colorectal And Lung Cancer
2026-09-14 23:19 · Yahoo
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
2026-09-11 19:39 · Yahoo
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says
2026-09-11 16:00 · Yahoo
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?
2026-09-04 17:32 · Yahoo
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-02 20:15 · Yahoo
Duncan Ferguson Joins Neovii Pharmaceuticals AG to Lead Global Commercial Expansion as Chief Commercial Officer
2026-09-01 20:48 · Yahoo
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
2026-09-01 16:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.